Prognosis of local recurrence in giant cell tumour of bone: what can we do?

2017 ◽  
Vol 122 (7) ◽  
pp. 505-519 ◽  
Author(s):  
Yifeng He ◽  
Ji Zhang ◽  
Xiaoyi Ding
Author(s):  
Lenian Zhou ◽  
Hongyi Zhu ◽  
Shanyi Lin ◽  
Hanqiang Jin ◽  
Zhaoyuan Zhang ◽  
...  

Abstract Background Extended curettage has increasingly become the preferred treatment for giant cell tumour of bone (GCTB), but the high recurrence rate after curettage poses a major challenge for orthopaedic surgeons. Computed tomography (CT) is valuable in the evaluation of GCTB. Our aim was to identify specific features of GCTB around the knee in pre-operative CT images that might have prognostic value for local recurrence. Methods We retrospectively analyzed data from 124 patients with primary GCTB around the knee who underwent extended curettage from 2010 through 2019. We collected demographic, clinical, and therapeutic data along with several CT-derived tumour characteristics. CT-derived tumor characteristics included tumour size, the distance between the tumour edge and articular surface (DTA), and destruction of posterior cortical bone (DPC). Akaike information criterion (AIC) was used to select which variables to enter into multivariate logistic regression models and to determine significant factors affecting recurrence. Results The total recurrence rate was 21.0% (26/124), and the average follow-up time was 69.5 ± 31.2 months (24–127 months). Age, DTA (< 2 mm), and DPC were significantly related to recurrence, as determined by multivariate logistic regression. The C-index of the final model was 0.79 (95% CI: 0.71 to 0.88), representing a good model for predicting recurrence. Conclusion Identifying certain features of GCTB around the knee on CT has prognostic value for patients treated with extended curettage. A three-factor model predicts tumour recurrence well after extended curettage.


2018 ◽  
pp. bcr-2017-221275
Author(s):  
Timothy Mark Morris ◽  
Zakareya Gamie ◽  
Kanishka Milton Ghosh ◽  
Kenneth Samora Rankin

2014 ◽  
Vol 119 (11) ◽  
pp. 861-870 ◽  
Author(s):  
Liang Chen ◽  
Xiao-Yi Ding ◽  
Chengs-Sheng Wang ◽  
Ming-Jue Si ◽  
Lian-Jun Du ◽  
...  

2015 ◽  
Vol 97-B (11) ◽  
pp. 1566-1571 ◽  
Author(s):  
A. A. Salunke ◽  
Y. Chen ◽  
X. Chen ◽  
J. H. Tan ◽  
G. Singh ◽  
...  

2010 ◽  
Vol 110 (6) ◽  
pp. 584-589 ◽  
Author(s):  
M.F. Pietschmann ◽  
R.A. Dietz ◽  
S. Utzschneider ◽  
A. Baur-Melnyk ◽  
V. Jansson ◽  
...  

2021 ◽  
Vol 103-B (1) ◽  
pp. 184-191
Author(s):  
David Louis Perrin ◽  
Julia D. Visgauss ◽  
David A. Wilson ◽  
Anthony M. Griffin ◽  
Albiruni R. Abdul Razak ◽  
...  

Aims Local recurrence remains a challenging and common problem following curettage and joint-sparing surgery for giant cell tumour of bone (GCTB). We previously reported a 15% local recurrence rate at a median follow-up of 30 months in 20 patients with high-risk GCTB treated with neoadjuvant Denosumab. The aim of this study was to determine if this initial favourable outcome following the use of Denosumab was maintained with longer follow-up. Methods Patients with GCTB of the limb considered high-risk for unsuccessful joint salvage, due to minimal periarticular and subchondral bone, large soft tissue mass, or pathological fracture, were treated with Denosumab followed by extended intralesional curettage with the goal of preserving the joint surface. Patients were followed for local recurrence, metastasis, and secondary sarcoma. Results A total of 25 patients with a mean age of 33.8 years (18 to 67) with high-risk GCTB received median six cycles of Denosumab before surgery. Tumours occurred most commonly around the knee (17/25, 68%). The median follow-up was 57 months (interquartile range (IQR) 13 to 88). The joint was salvaged in 23 patients (92%). Two required knee arthroplasty due to intra-articular fracture and arthritis. Local recurrence developed in 11 patients (44%) at a mean of 32.5 months (3 to 75) following surgery, of whom four underwent repeat curettage and joint salvage. One patient developed secondary osteosarcoma and another benign GCT lung metastases. Conclusion The use of Denosumab for joint salvage was associated with a higher than expected rate of local recurrence at 44%. Neoadjuvant Denosumab for joint-sparing procedures should be considered with caution in light of these results. Cite this article: Bone Joint J 2021;103-B(1):184–191.


Cureus ◽  
2020 ◽  
Author(s):  
Emma L Howard ◽  
Jonathan Gregory ◽  
Kim Tsoi ◽  
Scott Evans ◽  
Adrienne Flanagan ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document